Novavax Inc vs Starbucks Corp — how do they compare? Novavax Inc trades at $7.95 (market cap $1.31B), while Starbucks Corp trades at $108.13 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 92.8× Novavax Inc's market cap, and Starbucks Corp pays a 2.33% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SBUX | |
|---|---|---|
Market Cap | $1.31B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $108.37 |
52-Week Low | $6.22 | $78.46 |
Enterprise Value | $889.30M | $140.42B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.33% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Starbucks (SBUX) trades at $108.03, up 3.23% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 guidance, though valuation remains elevated at a P/E of 61.65. Recent news highlights a successful turnaround strategy under CEO Brian Niccol, with traffic recovery and margin expansion driving optimism.
The outlook remains positive with analyst consensus pointing to $113.60 price target, though high valuation and execution risks require monitoring. Key opportunities include sustained traffic growth and cost efficiency initiatives, while risks involve premium pricing sensitivity and competitive pressures in the coffee retail space.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →